Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Results

By Josh Kohn-Lindquist – Mar 30, 2026 at 5:18PM ESTExpandNYSE: BSXBoston ScientificToday's Change(-9.06%) $-6.27Current Price$62.90Key Data PointsMarket Cap$103BDay's Range$61.25 - $65.6752wk Range$61.25 - $109.50Volume2.2MAvg Vol15MGross Margin65.04%Boston Scientific (BSX 9.06%), a maker of medical devices for interventional specialties, closed Monday at $62.92, down 9.03%. The stock moved lower on Monday as investors analyzed new clinical trial information on the company’s Watchman heart implant. Trading volume reached 39.9 million shares, coming in about 163% above its three-month average of 15.2 million shares. Boston Scientific IPO'd in 1992 and has grown 1370% since going public.How the markets moved todayS&P 500 slipped 0.39% to finish Monday at 6,344, while the Nasdaq Composite declined 0.73% to close at 20,795. Among medical device peers, Medtronic closed at $85.78 (-1.56%) and Stryker ended at $326.05 (-0.42%), reflecting broader pressure across the group.What this means for investorsBoston Scientific provided an update on its CHAMPION-AF clinical trial, which tests its Watchman FLX heart implant versus existing oral anticoagulant (NOAC) treatment options. While management announced that the trial met all of its safety and efficacy endpoints, analysts were underwhelmed.Analysts at Wells Fargo, Leerink Partners, and Raymond James maintained outperform ratings on Boston Scientific stock but said the trial was “not a home run,” as growth from the medical device may not accelerate as much as hoped. That said, Boston Scientific is home to hundreds of medical devices, so investors shouldn’t panic over one lukewarm trial update. Furthermore, with the stock down 38% over the last year, Boston Scientific and its track record of success may be reasonably priced today at just 18 times forward earnings.Read NextMar 5, 2026 •By Eric Volkman3 Reasons Boston Scientific Stock Could Quietly 5X as the World AgesMar 30, 2026 •By Parkev Tatevosian, CFAWhy Is Teledoc Stock Crashing, and is it a Generational Buying Opportunity?Mar 30, 2026 •By David Jagielski, CPAEli Lilly's CEO Says This Could Be a Game Changer for Its BusinessMar 29, 2026 •By Reuben Gregg BrewerPrediction: Buying Pfizer Stock Today Could Set You Up for LifeMar 29, 2026 •By Thomas Niel1 Reason This Biotech Stock Could Triple Before Year-EndMar 30, 2026 •By Howard SmithStock Market Today, March 30: Fermi Shares Plunge After Wider Loss and No Tenant for Flagship AI ProjectAbout the AuthorJosh Kohn-Lindquist is a contributing Motley Fool stock market analyst covering consumer goods, industrials, and technology stocks. Previously, Josh was a senior mutual fund accountant at Gemini Fund Services. He holds a bachelor’s degree in business management from the University of South Dakota.TMFJorykoX@JorykoliStocks MentionedBoston ScientificNYSE: BSX$62.90(-9.06%)-$6.27*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.